TRAZIMERA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRAZIMERA (TRAZIMERA).
Trazimera is a humanized monoclonal antibody that binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2). It inhibits proliferation of tumor cells overexpressing HER2 and mediates antibody-dependent cellular cytotoxicity (ADCC).
| Metabolism | Trastuzumab is eliminated via catabolism, similar to endogenous immunoglobulins. It is not metabolized by cytochrome P450 enzymes; clearance involves reticuloendothelial system. |
| Excretion | Primarily via the reticuloendothelial system. Mean clearance 0.225 L/day. Elimination half-life is not dose-dependent. |
| Half-life | Terminal elimination half-life approximately 28 days (range 20–38 days) based on population pharmacokinetic analysis. |
| Protein binding | Approximately 95% bound to serum proteins, primarily albumin. |
| Volume of Distribution | Mean volume of distribution around 4.5 L (approximately 0.064 L/kg), suggesting limited extravascular distribution. |
| Bioavailability | Intravenous: 100%. |
| Onset of Action | Intravenous: Steady-state achieved by approximately 6 weeks of weekly dosing. |
| Duration of Action | Prolonged suppression of HER2 receptor signaling; clinical effect persists for weeks after cessation. Dosing every 3 weeks maintains therapeutic concentrations. |
For HER2-positive breast cancer, the recommended dose is 8 mg/kg intravenous infusion over 90 minutes on day 1 of cycle 1, followed by 6 mg/kg over 30-90 minutes every 3 weeks for the duration of therapy.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment is recommended for renal impairment. Trazimera is not significantly renally excreted; caution is advised in severe renal impairment due to potential toxicities. |
| Liver impairment | No specific dose adjustment for hepatic impairment is provided; however, it should be used with caution in patients with hepatic dysfunction as trastuzumab may cause hepatotoxicity. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; no recommended dosing. |
| Geriatric use | No specific dose adjustment is required for elderly patients; consider comorbidities and reduced organ function as a general precaution. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRAZIMERA (TRAZIMERA).
| Breastfeeding | Human data on trastuzumab in breast milk are limited. Trastuzumab is a large protein molecule that is expected to be present in breast milk at low concentrations with minimal oral bioavailability due to degradation in the infant's gastrointestinal tract. The milk-to-plasma ratio is not established. Caution is advised; consider the developmental and health benefits of breastfeeding along with the mother's clinical need for TRAZIMERA. |
| Teratogenic Risk | TRAZIMERA (trastuzumab) is an IgG1 monoclonal antibody that crosses the placenta during the second and third trimesters. Exposure in the second and third trimesters is associated with oligohydramnios, fetal renal impairment, and oligohydramnios sequence (pulmonary hypoplasia, skeletal abnormalities, neonatal death). No human data are available for first-trimester exposure; however, IgG antibodies do not cross the placenta significantly in the first trimester. Based on its mechanism (HER2 inhibition), potential fetal harm cannot be excluded in the first trimester. |
■ FDA Black Box Warning
Cardiomyopathy: Trastuzumab can cause left ventricular dysfunction, congestive heart failure, and cardiac failure. Assess left ventricular ejection fraction (LVEF) before and during treatment. Discontinue if clinically significant decline in LVEF occurs.
| Serious Effects |
["None known (no absolute contraindications based on clinical trials; use caution in patients with hypersensitivity to trastuzumab or any excipient)"]
| Precautions | ["Cardiomyopathy: Monitor LVEF; interrupt or discontinue if significant decline occurs.","Infusion reactions: Monitor during infusion; severe reactions may require discontinuation.","Pulmonary toxicity: Fatal pulmonary events reported; use caution in patients with pulmonary disease.","Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception during and after treatment."] |
Loading safety data…
| Fetal Monitoring | Monitor for signs and symptoms of congestive heart failure (CHF) and perform cardiac assessments (e.g., echocardiogram or MUGA scan) at baseline and every 3 months during and after treatment, especially in pregnant women. Monitor fetal development with serial ultrasounds for oligohydramnios and renal abnormalities if used during second or third trimester. Assess renal function in the neonate if exposure occurred. |
| Fertility Effects | Trastuzumab may impair female fertility. Ovarian function suppression has been reported in premenopausal women, potentially leading to reduced ovarian reserve and prolonged infertility. Effects on male fertility are unknown. |